Form 0920-1385 Chromoblastomycosis case report form

[NCEZID] Characteristics of Cases of Priority Fungal Diseases

Att 3g Chromoblastomycosis case report form

Chromoblastomycosis case report form

OMB: 0920-1385

Document [docx]
Download: docx | pdf

Form Approved

OMB No. 0920-1385

Exp. Date: 3/31/26


Case report form: Chromoblastomycosis in the United States

======================================================

Patient demographic characteristics

Unique patient ID: ___________ (site_####)

Site submitting case: _____________

Location of residence for patient (ZIP Code): _____________ OR [] Unknown

Age at diagnosis (years): ____________

Assigned sex at birth: [] Male [] Female OR [] Unknown

Gender identity: [] Male [] Female [] Transgender, non-binary, or another gender[] Prefer not to answer/Decline OR [] Unknown

Race and/or ethnicity (select all that apply and enter additional details in the spaces provided):

[] American Indian or Alaska Native

Enter, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Barrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, Maya, etc.



[] Asian – provide details below

[] Chinese [] Asian Indian [] Filipino [] Vietnamese [] Korean [] Japanese

Enter, for example, Pakistani, Hmong, Afghan, etc.



[] Black or African American – provide details below

[] African American [] Jamaican [] Haitian [] Nigerian [] Ethiopian [] Somali

Enter, for example, Trinidadian and Tobagonian, Ghanaian, Congolese, etc. ____________________________________________

[] Hispanic or Latino – provide details below

[] Mexican [] Puerto Rican [] Salvadoran [] Cuban [] Dominican [] Guatemalan

Enter, for example, Colombian, Honduran, Spaniard, etc. ____________________________________________

[] Middle Eastern or North African – provide details below

[] Lebanese [] Iranian [] Egyptian [] Syrian [] Iraqi [] Israeli

Enter, for example, Moroccan, Yemeni, Kurdish, etc. ____________________________________________


[] Native Hawaiian or Pacific Islander – provide details below

[] Native Hawaiian [] Samoan [] Chamorro [] Tongan [] Fijian [] Marshallese

Enter, for example, Chuukese, Palauan, Tahitian, etc. ____________________________________________


[] White – provide details below

[] English [] German [] Irish [] Italian [] Polish [] Scottish

Enter, for example, French, Swedish, Norwegian, etc. ____________________________________________




Monthly household income (USD) _____________________________

Occupation at time of presumed infection: ____________________________

Industry at time of presumed infection: ______________________________

======================================================

Underlying medical conditions (active or present in the 2 years before symptom onset)


Diabetes mellitus [] Yes [] No [] Unknown

Chronic kidney disease [] Yes [] No [] Unknown

If yes, on dialysis? [] Yes [] No [] Unknown

If yes, GFR < 60? [] Yes [] No


Liver cirrhosis? [] Yes [] No [] Unknown

Chronic hepatitis without cirrhosis? [] Yes [] No [] Unknown

If yes, [] Hep B [] Hep C


Immunocompromising condition [] Yes [] No [] Unknown

[] HIV infection

[] HIV infection without AIDS (CD4 ≥ 200)

[] HIV infection with AIDS (CD4 < 200) or chart diagnosis of advanced HIV disease

[] Cancer diagnosis, specify ________________

[] On chemotherapy, specify ___________________

Date of cancer diagnosis (mm/dd/yyyy): ________________

[] Transplantation,

[] Solid organ, specify organ ________________

[] Hematologic (stem cell)

Date of transplantation (mm/dd/yyyy): ________________

[] Immunosuppressive therapy, specify ________________

[] Other immunocompromised condition, specify _______________


Other major underlying condition not listed (specify): ________________________ 

======================================================

Exposure history

Has patient traveled or lived internationally in their life? [] Yes [] No [] Unknown

    • Country 1 ____________; Approximate duration of stay (years): 

    • Country 2 ____________; Approximate duration of stay (years): 

    • Country 3 ____________; Approximate duration of stay (years): 

    • Country 4 ____________; Approximate duration of stay (years): 

    • Country 5 ____________; Approximate duration of stay (years): 

Did the patient immigrate to the United States? [] Yes [] No [] Unknown

If yes, date of immigration (mm/dd/yyyy): _________________ [] Unknown

If yes, country immigrated from: ­­­­­­­________________ [] Unknown

Any traumatic inoculation recalled? [] Yes [] No [] Unknown

If yes, please describe geographic location (e.g., city, state): ______________

If yes, please describe the material involved (e.g., thorns, branches): _________

If yes, please describe any weather events (e.g., hurricane, flood): ____________

If yes, please indicate approximate date of traumatic inoculation (mm/dd/yyyy): _____________

Most likely source of infection, according to clinician ________________________________

======================================================

Diagnosis

Did patient have health care facility visits (health center, hospital, etc.) for mycetoma symptoms before visit with mycetoma diagnosis? [] Yes [] No [] Unknown 


If yes, how many visits? ____________ 


Were there misdiagnoses before being diagnosed with mycetoma [] Yes [] No [] Unknown 


What misdiagnoses, if any, did this patient have before being diagnosed with mycetoma (in the last 12 months):  

  • Please list all misdiagnoses: ____________________________________________ 


Laboratory testing (associated with diagnosis):


[] Dermoscopy [] Not performed [] Unknown if performed

date of procedure: ____________

[] Potassium hydroxide preparation [] Not performed [] Unknown if performed

date of preparation: ____________; result: ______________________

[] Skin or surgical biopsy [] Not performed [] Unknown if performed

date of collection (mm/dd/yyyy): ____________; result: ______________________

[] Fungal culture [] Not performed [] Unknown if performed

date of collection (mm/dd/yyyy): ____________; Positive/Negative: _____________ Organism(s): _____________________;

[] Broad range sequencing [] Not performed [] Unknown if performed

date of collection (mm/dd/yyyy): ____________; Type (e.g., 18s, ITS): ____________

Positive/Negative: _____________ Organism(s): _____________________;



======================================================

Signs and symptoms noted in medical chart:



Signs & Symptoms

Yes/No

Onset Date

Warty lesions



Raised and crusted lesions



Tumors



Infiltrative plaques



Nodules



Polymorphic lesions



Migraines



Pain



Itching



Edema



Syncope



Vomiting



Other symptoms, please describe:_______





Please indicate the specific location(s) of the body of the chromoblastomycosis lesions (check all that apply):

[] Head and neck

[] Trunk

[] Upper limbs

[] Buttocks, perineum, genitals

[] Lower limbs

Additional comments on anatomical location: ___________________________________



Disease severity:

[] Mild (solitary plaque or nodule less than 5 cm in diameter)

[] Moderate (single or multiple lesions with nodular, verrucous or plaque morphology, less than 15 cm in diameter, and involving a single or two adjacent skin areas)

[] Severe (extensive involvement of adjacent or nonadjacent skin areas)

Did mycetoma cause any form of disability: [] Yes [] No [] Unknown 

If yes, please fill out the table below:

Disability

Yes/No

Onset Date

Number of days with disability

Inability to walk




Impacts mobility/ability to walk




Inability to work






Treatment

Was the patient treated for chromoblastomycosis? 

[] Yes [] No [] Unknown [] Missing/Not documented 


If yes, list all therapeutic agents (e.g., antifungals, immune response modulators, antibiotics, steroids) in the table below:


 Therapeutic Agent Name 

Max Daily dose (mg/day) 

Route (e.g., IV, PO, IT) 

 Start Date 

Duration  

of Therapy 

Therapy ongoing  

at time of  

abstraction 

Discontinued due to toxicity. If yes, describe toxicity

Therapeutic Drug Monitoring (e.g., serum level of antifungal)


 

 

 

___ / ___ / ______ 

 

_____days 

 

[] Yes [] No 

[] Yes [] No 

--------------------- 

--------------------- 

[] Yes [] No 


Level 1:

Date:

Value:


Level 2:

Date:

Value


 

 

 

___ / ___ / ______ 

 

_____days 

 

[] Yes [] No 

[] Yes [] No 

--------------------- 

--------------------- 

[] Yes [] No 


Level 1:

Date:

Value:


Level 2:

Date:

Value

 

 

 

 

___ / ___ / ______ 

 

_____days 

 

[] Yes [] No 

[] Yes [] No 

--------------------- 

--------------------- 

[] Yes [] No 


Level 1:

Date:

Value:


Level 2:

Date:

Value

 

 

 

 

___ / ___ / ______ 

 

_____days 

 

[] Yes [] No 

[] Yes [] No 

--------------------- 

--------------------- 

[] Yes [] No 


Level 1:

Date:

Value:


Level 2:

Date:

Value

 

 

 

 

___ / ___ / ______ 

 

_____days 

 

[] Yes [] No 

[] Yes [] No 

--------------------- 

--------------------- 

[] Yes [] No 


Level 1:

Date:

Value:


Level 2:

Date:

Value

 

 

 

 

___ / ___ / ______ 

 

_____days 

 

[] Yes [] No 

[] Yes [] No 

--------------------- 

--------------------- 

[] Yes [] No 


Level 1:

Date:

Value:


Level 2:

Date:

Value



Notes about treatment: __________________________________________________________________________________________________________________________________________________________________________

Did the patient undergo surgical excision of the chromoblastomycosis lesion(s): [] Yes [] No [] Unknown

If yes, date of surgical excision (mm/dd/yyyy): _____________

Did the patient have cryotherapy: [] Yes [] No [] Unknown


Did the patient have heat therapy: [] Yes [] No [] Unknown


Did the patient have light-based therapy: [] Yes [] No [] Unknown



======================================================

Complications:

Outcome

Yes/No

Onset Date

Notes (e.g., location)

Tissue fibrosis




Secondary bacterial infection




Squamous cell carcinoma




Internal organ involvement




Amputation




Lymphedema






Did the chromoblastomycosis infection resolve? [] Yes [] No [] Since

If yes, what was the date of clinical resolution (disappearance of cutaneous manifestations with the exception of atrophic scarring) (mm/dd/yyyy):

If no, what was date of last follow-up (mm/dd/yyyy):

Did this patient die within 2 years after the chromoblastomycosis diagnosis? [] Yes [] No [] Unknown


If yes, was chromoblastomycosis a contributing factor in patient’s death? [] Yes [] No [] Unknown

Additional comments: __________________________________________________________________________________________________________________________________________________________________________

Appendix 2: Dermatology Life Quality Index Tool

Dermatology Life Quality Index Questionnaire:

  1. Over the last week, how itchy, sore, painful, or stinging has your skin problem been?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

  2. Over the last week, how embarrassed or self-conscious have you been because of your skin problem?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

  3. Over the last week, how much has your skin problem interfered with you going shopping or looking after your home or garden?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

    5. Not relevant

  4. Over the last week, how much has your skin problem influenced the clothes you wear?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

    5. Not relevant

  5. Over the last week, how much has your skin problem affected any social or leisure activities?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

    5. Not relevant

  6. Over the last week, how much has your skin problem made it difficult for your to do any sport?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

    5. Not relevant

  7. Over the last week, has your skin problem prevented you from working of studying

    1. Yes

    2. No

    3. Not relevant

      1. If no, over the last week how much has your skin problem been a problem at work or studying?

        1. A lot

        2. A little

        3. Not at all

  8. Over the last week, how much has your skin problem created problems with your partner or any of your close friends or relatives?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

    5. Not relevant

  9. Over the last week, how much has your skin problem caused any sexual difficulties?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

    5. Not relevant

  10. Over the last week, how much of a problem has the treatment for your skin problem been, for example by making your home messy, or by taking up time?

    1. Very much

    2. A lot

    3. A little

    4. Not at all

    5. Not relevant



CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-1385).


File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorSmith, Dallas (CDC/DDID/NCEZID/DFWED)
File Modified0000-00-00
File Created2025-01-17

© 2025 OMB.report | Privacy Policy